INNOGEN-B

2591
3.5051.27% ( -0.045 )
Delay Closed: Nov 16, 16:08:11

Overview

INNOGEN-B (2591)

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical...

Open
3.450
High
3.725
Low
3.450
Prev. Close
3.550
Volume
5.07M
Turnover
18.29M
Avg Price
3.609
Bid/Ask Ratio
88.10%
Amplitude
7.75%
52wk High
48.360
Volume Ratio
2.05
Turnover Ratio
1.21%
52wk Low
3.015
HK Mkt Cap
1.47B
Market CapHKD
1.60B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.843
EPSDynamic
-0.582
EPSStatic
--
BVPS
2.37
P/B
1.48
HK Shares
420.29M
Dividend YieldTTM
--
DividendTTM
--
Shares
456.82M
Min lot size
200
Currency
HKD

INNOGEN-B Analyst Rating

View more

Forecast & Rating

Aug 28, 2026
Price forecast
HK$20.50484.92%
Forecast & RatingStrong buy
2analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 13

    After a 10.53% weekly rebound faded, the stock reversed intraday: it opened at HK$3.740, printed the session high of HK$3.755 at 09:30 BJ and slid through the morning, touching HK$3.540 at 14:37 BJ before closing at HK$3.585, roughly 4% below the prior close of HK$3.735. Volatility has been sharp, with a HK$3.08 52-week low followed by a 12% snapback, while the company went through board resignations and a strategy committee reshuffle and named a new commercial vice president. Fundamentals show revenue growth alongside continuing losses: Q2 2026 revenue was HK$45.17 million, up 46.07% year on year, but the net loss reached HK$66.68 million, with a -147.61% net margin and -24.51% ROE, against PE of -4.2 and PB of 1.49. The stock is down 88.36% year to date and 92.68% below its 26 January high of HK$48.36, holding above its 20-day MA of 3.458 but below the 60-day MA of 3.698; whether two consecutive quarters of roughly 46% revenue growth can persist remains the swing factor for narrowing losses.

  2. Nov, 12

    Shares fell 3.4% to HK$3.735 in a spike-and-fade session: an early 09:35 high of HK$3.850 gave way to a steady slide and a 14:32 low of HK$3.670, on 7.74 million shares and 1.83% turnover. The pullback interrupts a rebound off the 3 November 52-week low of HK$3.015 that had included a one-day 12% surge, with board resignations and a strategy-committee reshuffle weighing on near-term sentiment. Fundamentals show the tension: Q2 revenue rose 46.07% year on year to HK$45.17 million, yet the HK$66.68 million net loss narrowed only 0.62%, leaving net margin at -147.6% and ROE at -24.51% while commercialization of lead GLP-1 product Yinuoqing stays early-stage. The stock is down 87.72% year to date and sits 92.28% below its 52-week high of HK$48.36, now just above the MA20 of HK$3.462 and close to the MA60 of HK$3.709, on 1.57x PB and a HK$1.71 billion market cap. Though it remains 23.88% above its 52-week low, with a new commercial vice president in place.

  3. Nov, 10

    Innogen (2591.HK) rose 5.84% to HK$3.895, staging a low-open, high-close rebound as discussion of GLP-1 commercialization potential gained attention and the company appointed Jin Bo as vice president to oversee product commercialization. The stock dipped to HK$3.670 at 09:38 BJ, then climbed to HK$4.020 at 13:28 before giving back part of the gain; turnover was HK$49.8 million with a 3.06% turnover rate. Q2 revenue was HK$45.17 million, up 46.07% year on year, while the net loss was HK$66.68 million and the net margin was -147.6%; loss per share was HK$0.146, narrowing 8.58% year on year, leaving the company with revenue growth and a narrower but still unprofitable profile. The price remains in a deep repair zone: down 87.2% year to date, 91.95% below the 52-week high of HK$48.36, but 29.19% above the 52-week low of HK$3.015 set on November 3, and above both MA20 and MA60 at HK$3.46 and HK$3.737; PB is 1.64x. Though reports of a sales head resignation and pressure on domestic GLP-1 product sales remain a reverse factor.

  4. Nov, 9

    Innogen-B rose 1.66% to HK$3.680 in a spike-and-fade session: after the 09:30 open it slipped to 3.610, peaked at 3.905 at 11:50 BJ, then gave back the entire gain into the close on HK$45.39 million of turnover. The move reads as sentiment repair after a steep decline, with a weekly recap showing a 10.53% rebound and Orient Securities reiterating commercialization potential for GLP-1 drugs, which keeps discussion around its core long-acting GLP-1 candidate alive. Fundamentals remain pre-profit: Q2 revenue rose 46.07% YoY to HK$45.17 million while net loss reached HK$66.68 million, with EPS of -HK$0.146 and PB of 1.55. The stock is still down 87.90% YTD and 92.39% below its 52-week high of HK$48.36, trading above the MA20 of 3.462 but below the MA60 of 3.782; though a sales head and several directors resigned earlier, leaving the rebound on a fragile base.

  5. Nov, 6

    Shares of 2591.HK fell 3.7% to HK$3.620 after a low-open, spike-and-fade session that ran from HK$3.500 to HK$3.750 before an afternoon pullback, as the recent resignation of the sales head and several directors kept attention on domestic GLP-1 commercialization challenges. Q2 2026 revenue rose 46.1% year on year to HK$45.2 million, yet the net loss remained HK$66.7 million and EPS was -HK$0.146, showing topline growth has not yet offset losses. The stock sits 20.1% above its 52-week low of HK$3.015 but 92.5% below the January high of HK$48.36 and down 88.1% year to date; it is above the MA20 of HK$3.456 but below the MA60 of HK$3.838. The appointment of former Beijing Dingfeng Bio CEO Jin Bo as vice president adds commercial leadership, though sales-system changes and GLP-1 competition remain in focus.

News

Bullish vs. Bearish — Last 3 Months

13.3k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • M
    momoM

    $INNOGEN-B(02591.HK) Everyone draws lots...